Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001 Treatment in AML Patients at ASH 2021 Immunicum AB (“Immunicum”, publ; IMMU.ST), a biopharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback